Founded in 2017, IASO Bio is one of the few commercial-stage biopharmaceutical companies in the Advanced Therapy Medicinal Product (ATMP) sector bringing China’s breakthrough innovations to the global market. We specialize in developing cell therapies and biologics for hematological malignancies and autoimmune diseases. Our industry-leading, fully integrated platforms leverage cutting-edge technologies that span the entire product lifecycle—from discovery and development to manufacturing and commercialization.
We have established a robust and synergistic pipeline, reflecting our commitment to making transformative cell therapies broadly accessible to patients worldwide. Our current portfolio includes ten products and product candidates, anchored by our core product, Equecabtagene Autoleucel (eque-cel). The CAR-T therapy Eque-cel has been approved in China for the treatment of relapsed or refractory multiple myeloma (r/r MM) in patients who have progressed after at least three prior lines of therapy. It is also being developed for use in earlier lines of r/r MM treatment and for autoimmune diseases, including myasthenia gravis (MG), multiple sclerosis (MS), and systemic lupus erythematosus (SLE)/lupus nephritis (LN). Beyond eque-cel, we are developing nine additional therapeutic candidates—including three autologous chimeric antigen receptor T-cell (CAR-T) therapies, five in vivo CAR-T cell therapies, and one antibody product candidate.
We collaborate with leading biotechnology and biopharmaceutical companies such as Innovent, Sana, Cabaletta, and Umoja, as well as top-tier academic institutions and hospitals, to strengthen our product development capabilities.
Leveraging our strong execution capability, an integrated and experienced management team in ATMPs, a robust pipeline, and advanced manufacturing and CMC capabilities, IASO Bio remains committed to making transformative cell therapies broadly accessible to patients worldwide.
Eque-cel BLA approved in Hong Kong China for r/r MM
IASO Bio partners with Korea's GC Cell to bring CAR-T therapy to Korea;
Eque-cel received CTN approval from MHLW in Japan for r/r MM
Completed Series C2 Financing and raised RMB215 million
Eque-cel received Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea
Eque-cel received Orphan Drug Designation from the Saudi Food and Drug Authority
Eque-cel BLA approved in Macau China for r/r MM
Eque-cel BLA accepted in Hong Kong China for r/r MM
Eque-cel BLA accepted in Singapore for r/r MM
Fucaso®(eque-cel) achieved cross-border supply
Eque-cel received IND approval from FDA for SLE and LN
IASO782 received IND approval from NMPA for SLE;
Eque-cel received IND from FDA for MS;
Deepened our strategic collaboration with Innovent, which also became our strategic shareholder
IASO118 received IND approval from NMPA for r/r MM
Eque-cel received IND approval from FDA for MG
Eque-cel received IND approval from NMPA for second- and third-line of MM
Eque-cel received IND approval from NMPA for MG
Entered into research collaboration with Umoja Biopharm to bring off-the-shell therapies to patients with hematological malignancies
IASO782 received IND approval from U.S. FDA and NMPA;
The BLA for eque-cel for r/r MM was approved by the NMPA
Company was converted into a joint stock company with limited liability
Completed Series C1 financing and raised RMB430 million
Entered into exclusive license agreement with Cabaletta Bio for clinically validated CD19 binder
The BLA for eque-cel for r/r MM was accepted by the NMPA
Nanjing manufacturing base was granted Drug Manufacturing License for CAR-T cell therapy products
Completed Series C/C+ financing and raised US$88 million
Our U.S. R&D laboratory commenced operation
Received IND approval for IASO120 for r/r B-NHL and r/r B-ALL from the NMPA
Eque-cel received Breakthrough Therapy Designation from NMPA for r/r MM
The first autoimmune diesase patient was enrolled
Commercial facility in Nanjing commenced operation
First patient enrolled for the Phase II trial of Eque-cel for r/r MM
Completed Series B financing and raised US$30 million from Hillhouse as the exclusive investor
Completed Series A financing and raised US$30 million from Hillhouse as the exclusive investor
Received IND approval for eque-cel for r/r MM from the NMPA
Proprietary human antibody library established
Established a GMP platform for research, development and intermediate testing of plasmids, viruses and cell;
Partnered with Innovent Biologics (Suzhou) in the development of autogenous CAR-T product based on
BCMA targets
IASO Bio established in the PRC as a limited liability company
